Is the Covid vaccine safe in children who have had a systemic multi-inflammatory reaction after the virus?

A multicenter observational study, the largest of its kind that analyzes

in

, has provided more data regarding whether the vaccine can increase the

in young people who have suffered from

, a rare and life-threatening immune reaction that can occur following SARS-CoV-2 infection.

.

The study, supported by the National Institutes of Health (NIH) of the United States and published in JAMA Network Open, has not found

after suffering from the aforementioned syndrome: in children and adolescents who received a vaccine for Covid-19 after of having (SIM-C) there have been no reports of serious complications,

or

which "shows that it is safe to receive a vaccine after having SIM-C" , reflects the article.

After vaccination, about half of the participants experienced

, such as pain in the arm and fatigue.

Multisystem inflammatory syndrome is a little-known condition -some authors consider it a late side effect of Covid-19 infection-, which affects 1 in 3,000 to 4,000 children and adolescents who have passed the viral infection, according to data from the Centers for Disease Control and Prevention (CDC).

It appears weeks after infection by Covid-19 and, in some cases, it can cause

, which, however, usually recovers favorably.

The

;

from mild to inflammation of the heart muscle:

.

The work reveals that some families and health professionals have

whether Covid-19 vaccines could cause

in people with

, including a recurrence of the disease, but data were lacking. about this theme.

cross-sectional data

In November 2022, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) gave its go-ahead to the vaccine against the BA.4 and BA.5 variants of omicron from Pfizer and BioNTech for

.

vaccine

adapted to BA.4 and BA.5 was previously authorized in the European Union (EU) as

.

The new cross-sectional study included

(21 in the United States and 1 in Canada) that participated in the NHLBI

Long-Term Outcomes After Multisystem Inflammatory Syndrome in Children (

It enrolled

with prior SIM-C who were eligible for Covid-19 vaccination.

Of this group, 185 (48.1%) received

of vaccine.

The median age was 12.2 years and 73.5% were male.

Participants were racially diverse: 24.3% Black, 31.9% Hispanic, and 28.6% White.

The median

to the first vaccine dose was 9 months.

Of those who received a vaccine after SIM-C,

, mainly arm pain and fatigue, occurred in 49% of them, similar to the general population.

There were no reports of serious complications, such as myocarditis or recurrence of the syndrome.

risk groups

Matthew D. Elias

, a pediatric cardiologist at the Children's Hospital of Philadelphia and professor of pediatrics at the University of Pennsylvania, Philadelphia, USA, notes: "We are very comfortable with the results and these safety data should be reassuring to families and healthcare professionals. health when considering and recommending vaccination.

For

, co-author of the paper and a pediatric cardiologist at Boston Children's Hospital and assistant professor of pediatrics at Harvard Medical School, Boston, the findings support the CDC's

that "patients with a history of SIM-C receive a vaccine against Covid-19

and that it is safe to do so.

"Given the

that Covid-19 can cause, it is essential to continue the development, testing and deployment of

in risk groups and the general population," says

, director of the NIH's National Heart, Lung, and Blood Institute (NHLBI).

So far, in the United States more than 9,000 patients have been diagnosed with SIM-C of the 74 have died, according to data from the CDC.

However, the disease

, according to studies by other international research groups.

"A large part of that reduction is that the Covid-19 vaccination

against this rare condition in those who have received it," according to Dionne.

Although

with SIM-C make a complete

, some studies have suggested that

after suffering from the syndrome, "so long-term outcome studies will be beneficial," say the researchers. researchers.

According to the criteria of The Trust Project

Know more

• Infectious diseases

• Pediatrics

• Covid 19